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Abstract  
AIM: We examined the role that immunoglobulin GM 23 and KM allotypes—genetic markers of γ 
and κ chains, respectively—play in response to treatment of hepatitis C virus (HCV) infection in 
Egyptian patients.  
MATERIAL AND METHODS: A total of 120 persons who had responded to HCV treatment and 
125 with persistent HCV infection were genotyped for the presence of GM23 and KM determinants. 
HLA –C genotyping was also done. 
RESULTS: Association of GM 23+ and KM3 was significantly associated with non response to 
treatment (P < 0.0001). Individuals who lacked this GM genotype (but were positive for KM1,2 and 
3) were likely to respond to treatment (P=0.045). Association of heterozygous GM23 (+/-) with KM 
1,2 and 3 or KM3 alone was significantly associated with SVR (P = 0.001) and (P = 0.0001) 
respectively. Particular combinations of HLA and GM genotypes were associated significantly with 
the response to HCV treatment. The combination of HLAC2C2 and GM23+ was associated with 
persistence of infection (P = 0.027) while the association of HLAC2C2 and heterozygous GM23+/- 
was associated with SVR (P = 0.001).The association of HLAC1C1 and heterozygous GM23+/- 
was significantly associated with SVR (P = 0.001) and also subjects with HLA C1/C2 and 
heterozygous GM23+/- were likely to respond to treatment (P = 0.003) while subjects with HLA 
C1/C2 and GM23+ show tendency to resist to treatment (P = 0.0001). 
CONCLUSION: Our results didn’t support a role for KM allotypes, GM23 allotype plays a role in the 
persistence of HCV infection in the presence or absence of KM1,3. Interaction between certain GM 
and HLA-C genotypes may favor adequate response to interferon based therapies.  
 
 
 
 
 
Introduction 
 
Hepatitis C virus genotype 4 (HCV-4) is the 
most common variant of HCV in Egypt. Pegylated IFN 
and ribavirin combination therapy has dramatically 
improved the treatment response rates, with recent 
clinical trials showing rates that exceed 60%.There 
are marked racial differences in rates of clearance of 
HCV and in responses to interferon-based therapies 
which may, at least in part, be due to the host genetic 
differences [1]. Among the host genetic factors, genes 
of the major histocompatibility complex (HLA) have 
been the primary focus of studies [2]. The HLA-C 
genes could influence the outcome of HCV infection 
by regulating the activity of natural killer (NK) cells. 
The killer immunoglobulin-like receptors (KIR) on NK 
cells bind their HLA-C ligands on target cells with 
differential affinity [3]. In addition, Pandey et al 
demonstrated the role of interactive effects of GM and 
HLA genotypes in the outcome of HCV infection. 
They also reported involvement of 
immunoglobulin (Ig) GM and KM allotypes—genetic 
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markers of gamma and alpha chains, respectively—in 
the outcome of HCV infection [1]. Allotypes of IgG 
proteins are defined by the expression of unique 
epitopes recognized by unique serologic reagents. 
Allotypes expressed on the constant region of IgG 
heavy chain are designated as Gm (Genetic marker) 
together with the subclass, e.g: G2m and the allotype 
number, e.g: G2m23. The heavy chains of IgG2 
proteins may express the Gm23 allotype that is 
correlated with the presence of CH2 methionine at 
residue 282 and CH1 threonine 189. 
The human genome has one kappa constant 
gene. There are three kappa chain allotypes 
designated Km1, Km2 and Km3 that define three Km 
alleles: Km1, that correlates with valine153 and 
leucine 191, Km1,2 that correlates with alanine 153 
and leucine 191 and Km3 that correlates with alanine 
153 and valine 191 [4].  
The HCV core protein has Fc receptor (Fc 
gamma R)-like properties, which the virus probably 
exploits to modulate the effector functions of the host 
immune cells, resulting in the evasion of 
immunosurveillance [5].  
Previous studies revealed that binding of IgG2 
of GM23+ allotype to HCV core protein was 
significantly higher than that of GM23- allotype, IgG2 
antibodies directed to the core protein in subjects with 
this determinant are more likely to have their Fc 
domains scavenged, thereby reducing their 
immunological competence to eliminate the virus or 
circulating nucleocapsids through ADCC and other 
Fc-mediated effector mechanisms. These studies 
revealed a higher prevalence of GM23 in subjects with 
persistent HCV infection compared to those who have 
cleared the virus [1]. 
The aim of the present work is to assess the 
role of GM23 and Km allotypes as well as their 
interaction with HLA –C type for the prediction of 
sustained virologic response (SVR) in patients with 
chronic HCV before initiation of antiviral therapy in 
order to be able to estimate the potential for treatment 
success. 
 
 
Material and Methods 
 
Subjects 
The study subjects were recruited from 
several liver centres in Cairo and Giza (Egypt). Many 
of these patients have received their interferon 
treatment in Liver Institute of Cairo University. Two 
groups of cases were participated in this study 
according to standard criteria: 
1-125 cases of chronic HCV patients (non-
responder to Interferon therapy). 
2-116 cases Sustained virological response 
(SVR). The patient had a negative HCV-RNA after 6 
months of completing 48 weeks (nearly one year) 
therapy. Patients were treated by either Pegylated or 
short –acting Interferon along with ribavirin [6]. 
  
Exclusion Criteria 
All the cases with HIV, HBV, and shistosoma 
were excluded .All chronic HCV participants with 
immune hepatitis or liver complications were 
excluded. 
 
Questionnaire and Clinical Examination 
A written well informed consent was taken 
from all the participants. All participants were 
subjected to full personal and medical history; clinical 
examination and the status of the liver and spleen 
were evaluated by ultrasonography. All the cases with 
history of bilharzial infection and treatment, previous 
surgery and blood transfusion were excluded. Type of 
treatment, its duration and response were recorded. 
The study was approved by the Ethical Committee of 
the National Research Centre. 
 
Laboratory Investigations 
Estimation of HIV, hepatitis B surface antigen 
(HBsAg), HBcAb, HBeAg and shistosoma IgG were 
done by commercially available ELISA kits to exclude 
the positive cases. ANA, ASMA, AMA and LKM were 
also measured to exclude immune hepatitis. 
The presence of HCV antibodies was 
determined by third-generation enzyme linked 
immunosorbent assay (ELISA; CTK-Bioteck-USA), 
Liver function tests including ALT (alanine 
transaminase), AST (aspartate transaminase), ALP 
(alkaline phosphatase) and albumin were assayed 
using Olympus auto analyser AU400 (Olympus 
Diagnostica, Japan). 
 
Detection of HCV-RNA by Real Time PCR 
and HCV Genotyping 
Viral RNA was extracted from patient’s 
plasma using the QIAamp Viral RNA Kit (Qiagen 
Hilden, Germany, Cat no. 52904) according to the 
manufacturer's protocol. HCV RNA was detected by 
commercially available Toyobo RNA-direct real time 
PCR kit on SLAN Real Time PCR Detection System, 
LG Lifescience, Korea. The HCV genotype was 
defined by the reverse line probe assay (INNO-LIPA 
v.1.0, innogenetics, Ghent, Belgium) according to the 
manufacturer’s instruction.  
Determination of immunoglobulin gamma (GM 
23) and immunoglobulin kappa (KM) allotypes: 
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GM23 (valine-to-methionine substitution, a 
G→A transition in the CH2 region of the γ2 gene) is 
determined by use of a nested-PCR–restriction 
fragment length 24 polymorphism (PCR-RFLP) 
method. In brief, a 915 bp region of the γ 2 gene that 
incorporates the site for the allelic substitution is 
amplified by use of primers 5'-
AAATGTTGTGTCGAGTGCCC-3' and 5'-
GGCTTGCCGGCCGTGGCAC-3'. The conditions are 
4mn at 94˚C, 30 cycles (45 s at 94˚C, 45 s at 59˚C, 1 
min 15 s at 72˚C), and an extension cycle of 10 s at 
72˚C. A 197 bp segment is further amplified from this 
915 bp fragment, by use of primers 5'-
GCACCACCTGTGGCAGGACC-3' and  
5'-TTGAACTGCTCCTCCCGTGG-3'. 
Digestion of the amplified product by the restriction 
enzyme NlaIII run on a7% polyacrylamide (38:2 
acrylamide : bisacrylamide) non denaturing gel in TBE 
buffer for 3 h at 7 V/cm and stained with ethidium 
bromide, result in the following products 
corresponding to the following 3 genotypes: GM23+, 
90 bp, 63 bp, and 44 bp; GM23−, 134 bp and 63 bp; 
and GM23+,23−, 134 bp, 90 bp, 63 bp, and 44 bp [7].  
κ-Chain determinants KM1 and KM3 were 
characterized by a PCR-RFLP techniqueusing primers 
5'-ACTGTGGCTGCACCATCTGTCT-3' and 5'-
TCAGGCTGGAACTGAGGAGCAG-3'. The optimal 
conditions for PCR are denaturation at 94˚C for 1 min, 
30 cycles at 68˚C for 1 min, and an extension cycle of 
1 min at 72˚C. Following PCR amplification, digestion 
of the amplified product (360 bp) by the restriction 
enzyme AccI result in the following products 
corresponding to the following 3 genotypes: KM1, 360 
bp; KM3, 247 bp and 113 bp; and KM1,3, 360 bp, 247 
bp, and 113 bp [8].  
Three alleles—KM1, KM1,2, and KM3—
segregate at the KM locus. The KM1 allele is 
extremely rare, and > 98% of subjects positive for 
KM1 are also positive for KM2; thus, positivity for KM1 
includes positivity for both KM1 and KM1,2 alleles. 
 
HLA Class I Typing 
Genomic DNA was extracted from peripheral 
blood mononuclear cells using the QIAmp DNA minikit 
(Qiagen) according to the manufacturer’s instructions. 
HLA-C locus was genotyped by sequence-specific 
oligonucleotide probe protocols using LABType® SSO 
Typing kit (ONE LAMBDA,INC): LABType® applies 
Luminex® technology to the reverse SSO DNA typing 
method according to manufacturer’s Instructions. 
Individuals from the two groups (persistent and SVR) 
were categorized in HLA-C1 and HLA-C2 according to 
their genotyping data. HLA-C1 and -C2 molecules 
possess asparagines and lysine at residue 80, 
respectively. 
 
 
Statistical analysis 
Statistical analysis were done using computer 
program SPSS (Statistical Package for the Social 
Science; SPSS Inc., Chicago, IL, USA) version 18. 
Data were statistically described in terms of 
frequencies (number of cases) and percentages. Chi 
square (
2
) test was used for comparing qualitative 
data. P-values less than 0.05 were considered 
statistically significant.  
 
 
Results 
 
This study included 245 patients with HCV 
infection; 120 cases of SVR and 125 chronic HCV 
cases. The age of participants ranged between 20-50 
years and 228 of the participated cases were males 
and 34 were females. The HIV, hepatitis B surface 
antigen (HBsAg), HBcAb, HBeAg and shistosoma IgG 
of all the included cases were negative. ANA, ASMA, 
AMA and LKM of all the included cases were also 
negative. 
The distribution of GM 23 and KM genotypes 
in relation to response and non response to HCV 
treatment is given in Table 1. 
Table1: Distribution of GM23 and KM genotypes in relation to 
response and non response to HCV treatment. 
Genotype 
Persistent HCV 
N (%) 
SVR 
N (%) 
GM 23+ 95 (79.2%) 40 (34.4%) 
GM 23- 20 (16.7%) 35 (30.1%) 
GM 23+/- 5(4.1%) 41 (35.3%) 
KM 1,2 2 (1.7%) 0 
KM 3 40 (34.8%) 46 (40%) 
KM 1,2,3 73 (63.5%) 69(60%) 
Persistence n: 125 cases, failed GM23 typing: 5 cases, failed KM typing: 10 cases. SVR n: 
120 cases, failed GM23 typing: 4 cases, failed KM typing: 5 cases. 
 
Association of GM 23+ and KM3 was 
significantly associated with non response to ttt (P < 
0.0001). Individuals who lacked GM 23genotype (but 
were positive for KM1,2 and 3) were likely to respond 
to treatment (P = 0.045). Association of heterozygous 
GM23(+/-) with KM 1,2 and 3 or KM3 alone was 
significantly associated with SVR (P = 0.001) and (P = 
0.0001) respectively (Table 2). 
Table 2: Distribution of combined GM 23and KM 1,2,3 
genotypes in relation to response and non response to HCV 
treatment. 
Genotype 
Chronic HCV 
115 (%) 
HCV (SVR) 
114 (%) 
Chi-square P-value 
GM23+/KM1,2,3 55 (47.8) 29 (25.4) 12.35 P< 0.0001 
GM23+/KM1,2 1 (0.86) 0 1.382 0.240 
GM23+/KM3 33 (28.7) 11(9.65) 13.38 P< 0.0001 
GM23-/KM1,2,3 13 (11.3) 24 (20.9) 4.019 0.045 
GM23-/KM1,2 1 (0.86) 0 1.382 0.240 
GM23-/KM3 6 (5.2) 10 (8.8) 1.113 0.291 
GM23(+/-)/KM1,2,3 5 (4.35) 20 (17.5) 10.251 P=0.001 
GM23(+/-)/KM1,2 0 0 Cannot calculated 
GM23(+/-)/KM3 1 (0.86) 20(17.5) 19.11 P< 0.0001 
 
Particular combinations of HLA and GM 
genotypes were associated significantly with the 
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response to HCV treatment. The combination of 
HLAC2C2 and GM23+ was associated with 
persistence of infection (P = 0.027) while the 
association of HLAC2C2 and heterozygous GM23+/- 
was associated with SVR (P = 0.001). 
The association of HLAC1C1 and 
heterozygous GM23+/- was significantly associated 
with SVR (P = 0.001) and also subjects with HLA 
C1/C2 and heterozygous GM23+/- were likely to 
respond to treatment (P = 0.003) while subjects with 
HLA C1/C2 and GM23+ show tendency to resist to 
treatment (P = 0.0001) (Table3). 
Table 3: Distribution of combined HLA- C and IgG(GM 23) 
genotypes in relation to response and non response to HCV 
treatment. 
Genotype 
HLA/GM 
Chronic HCV 
120 (%) 
SVR 
116 (%) 
Chi-square P-value 
C1C1/GM23+ 24 (20%) 16 (13.8%) 1.614 0.204 
C1C1/GM23- 7 (5.8%) 14 (12.06%) 2.829 0.093 
C1C1/GM23+/- 2 (1.7%) 15 (12.9%) 11.19 0.001 
C2C2/GM23+ 25 (20.8%) 12 (10.3%) 4.908 0.027 
C2C2/GM23- 4 (3.3%) 7 (6.0%) 0.968 0.325 
C2C2/GM23+/- 0 11 (9.4%) 11.94 0.001 
C1C2/GM23+ 46 (38.3%) 12 (10.3%) 24.93 <0.001 
C1C2/GM23- 9 (7.5%) 14 (12.1%) 1.400 0.237 
C1C2/GM23+/- 3 (2.5%) 15 (12.9%) 9.11 0.003 
 
 
 
Discussion 
 
Immunoglobulin (Ig) GM and KM allotypes—
hereditary antigenic determinants of IgG heavy chains 
and kappa-type light chains, respectively—are 
associated with viral immunological properties and 
thus are ideal candidate genetic systems for 
investigations to identify risk-conferring factors in HCV 
pathogenesis [9].  
In the current study, we found that GM23+ 
allotype was more prevalent in chronic cases than in 
the SVR group (Table1). Pandey et al, showed that 
the prevalence of the GM23-carrying genotype was 
slightly higher in the group with persistent HCV 
infection than in the group who had cleared the virus 
[10] —a finding that is consistent with the observation 
that GM23-carrying IgG2 has a higher affinity for 
binding to the core protein than does its allelic 
counterpart. Previous studies have established that 
the recombinant HCV core protein does not bind to 
the Fab fragments of “nonimmune” IgG, the binding 
between IgG2 and the HCV core protein involve the 
Fc region of the IgG2 molecules. The differential 
binding of the HCV core protein to the GM23-
disparate IgG2 proteins influence the strategies 
employed by this virus to evade host 
immunosurveillance. Fc gammaR-like HCV core 
protein binds anti-core antibodies by “bipolar 
bridging.” In this model, the Fab part of the antibody 
molecule (paratope) binds to its antigenic target 
(epitope), whereas the Fc part of the antibody binds to 
the Fc gamma R-like binding site on the viral protein 
[5]. This binding may offer survival advantage to the 
virus by sterically hindering the access of Fc R-
expressing effector cells to HCV-infected cells. The 
HCV core protein may scavenge the Fc domains of 
anti-core antibodies after the binding of their 
paratopes to their antigenic target, thereby interfering 
with the effector functions—such as antibody-
dependent cellular cytotoxicity (ADCC)—mediated by 
the Fc domain of the bound antibody. Although 
antibody responses to HCV proteins are 
predominantly of IgG1 and IgG3 subclasses, 
antibodies of the IgG2 isotype have also been 
reported [11].  
In our study, we didn’t found an interactive 
effect of GM23 allotype and KM allotypes , analysis of 
the results in Table 2 revealed that individuals who 
lacked or were heterozygous for GM23 allotype and 
were positive for KM1,3 were likely to respond to 
treatment and clear the infection but in the presence 
of homozygous GM23 (and in the presence of KM1,3), 
subjects were less likely to respond to treatment. Our 
results didn’t support a role for KM allotypes. In a 
study done by Pandey et al (2004), he reported that 
subjects with GM 1,17 5,13 and KM 1,3 phenotypes 
were over three times (odds ratio [OR], 3.57; 95% 
confidence interval [CI], 1.44 to 8.87) as likely to clear 
the infection as the subjects who lacked these 
phenotypes. This GM phenotype had a similar 
association with clearance in the absence of KM 3 
(OR, 2.75; 95% CI, 1.21 to 6.23). The presence of GM 
1, 3, 17, 23, 5, 13 phenotype (in the absence of KM 3) 
was associated with persistence (OR, 0.21; 95% CI, 
0.06 to 0.77), while its absence (in the presence of 
KM 1,3) was associated with the clearance of infection 
[9]. Therefore, in accordance with our results GM23 
allotype plays a role in the persistence of HCV 
infection in the presence or absence of KM3. 
In the present study, we found interactive 
effects of GM and HLA genotypes to respond or not to 
interferon based therapies. 
Our results show that subjects with HLAC2C2 
or HLAC1C2 and homozygous GM23+ were likely to 
resist to treatment (P = 0.027 and P = 0.0001 
respectively), while subjects with HLAC1C1 or 
HLAC1C2 and heterozygous GM23+/- have tendency 
to respond to treatment (P = 0.001 and P = 0.003 
respectively). 
The HLA-C genes investigated in this study 
could influence the outcome of HCV infection by 
regulating the activity of natural killer (NK) cells, key 
players in anti-viral immunity. Particular allelic 
combinations of KIR and HLA-C genes have been 
reported to be associated with the resolution of HCV 
infection in one study [3], and confirmed in our 
previous study [12]). In the study done by Khakoo et 
al, on Caucasian and African Americans, the 
frequency of HLA-C1homozygosity was higher in 
individuals with resolved infections. They suggested 
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that HLA-C1homozygosity might have a protective 
effect on HCV infected hosts, because of the capacity 
of these molecules to present antigens that have 
stronger affinities for cytotoxic T cells [3]. 
Previous studies showed that binding of IgG2 
of GM23(+) allotype to HCV core protein was 
significantly higher than that of GM23(-) allotype, IgG2 
antibodies directed to the core protein subjects with 
this determinant (GM23) are more likely to have their 
Fc domains scavenged, thereby reducing their 
immunological competence to eliminate the virus or 
circulating nucleocapsids through ADCC and other 
Fc-mediated effector mechanisms [5] . Therefore ,the 
interactive effect between both HLA-C groups and the 
presence or absence of GM 23allotype observed here 
could be explained by the additive effect of NK-
dependent ADCC against HCV-infected cells by the 
HLA-C molecules and the influence of GM23 on the 
virus to evade host immune response. Specific 
combinations of HLA-C and GM genes may favour 
adequate response to interferon based therapy.  
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